Filing Details
- Accession Number:
- 0001209191-20-006279
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-04 16:10:16
- Reporting Period:
- 2020-01-31
- Accepted Time:
- 2020-02-04 16:10:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-01-31 | 4,692 | $187.53 | 37,932 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-01-31 | 4,692 | $238.65 | 33,240 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-03 | 2,156 | $91.05 | 35,396 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-03 | 1,554 | $86.52 | 36,950 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-02-03 | 440 | $228.90 | 36,510 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-03 | 530 | $229.99 | 35,980 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-03 | 1,300 | $231.16 | 34,680 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-03 | 900 | $231.87 | 33,780 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-03 | 540 | $232.71 | 33,240 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-01-31 | 4,692 | $0.00 | 4,692 | $187.53 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-02-03 | 2,156 | $0.00 | 2,156 | $91.05 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-02-03 | 1,554 | $0.00 | 1,554 | $86.52 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 20,334 | 2029-02-05 | No | 4 | M | Direct | |
| 0 | 2026-02-01 | No | 4 | M | Direct | |
| 6,213 | 2027-02-02 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $228.90 (range $228.37 to $229.11).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $229.99 (range $229.48 to $230.46).
- Open market sales reported on this line occurred at a weighted average price of $231.16 (range $230.48 to $231.47).
- Open market sales reported on this line occurred at a weighted average price of $231.87 (range $231.50 to $232.44).
- Open market sales reported on this line occurred at a weighted average price of $232.71 (range $232.50 to $232.94).
- The option vests in 16 quarterly installments from 02/06/2019.
- Fully vested.
- The option vests in 16 quarterly installments from 02/03/2017.
Billionaire Hedge Funds
